129 related articles for article (PubMed ID: 33472203)
1. Gliomatosis Cerebri Growth Pattern: Association of Differential First-Line Treatment with Overall Survival in WHO Grade II and III Gliomas.
Divé I; Steidl E; Wagner M; Filipski K; Burger MC; Franz K; Harter PN; Bähr O; Fokas E; Herrlinger U; Steinbach JP
Oncology; 2021; 99(4):215-224. PubMed ID: 33472203
[TBL] [Abstract][Full Text] [Related]
2. A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy.
Steidl E; Filipski K; Zeiner PS; Wagner M; Fokas E; Forster MT; Ronellenfitsch MW; Divé I; Steinbach JP; Harter PN; Bähr O
J Cancer Res Clin Oncol; 2021 Aug; 147(8):2373-2383. PubMed ID: 33538917
[TBL] [Abstract][Full Text] [Related]
3. Gliomatosis cerebri: no evidence for a separate brain tumor entity.
Herrlinger U; Jones DTW; Glas M; Hattingen E; Gramatzki D; Stuplich M; Felsberg J; Bähr O; Gielen GH; Simon M; Wiewrodt D; Schabet M; Hovestadt V; Capper D; Steinbach JP; von Deimling A; Lichter P; Pfister SM; Weller M; Reifenberger G
Acta Neuropathol; 2016 Feb; 131(2):309-319. PubMed ID: 26493382
[TBL] [Abstract][Full Text] [Related]
4. Revisiting prognostic factors of gliomatosis cerebri in adult-type diffuse gliomas.
Shin I; Sim Y; Choi SH; Park YW; Lee N; Ahn SS; Chang JH; Kim SH; Lee SK
J Neurooncol; 2024 Jun; 168(2):239-247. PubMed ID: 38700610
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide.
Wahl M; Phillips JJ; Molinaro AM; Lin Y; Perry A; Haas-Kogan DA; Costello JF; Dayal M; Butowski N; Clarke JL; Prados M; Nelson S; Berger MS; Chang SM
Neuro Oncol; 2017 Feb; 19(2):242-251. PubMed ID: 27571885
[TBL] [Abstract][Full Text] [Related]
6. MRI features predict survival and molecular markers in diffuse lower-grade gliomas.
Zhou H; Vallières M; Bai HX; Su C; Tang H; Oldridge D; Zhang Z; Xiao B; Liao W; Tao Y; Zhou J; Zhang P; Yang L
Neuro Oncol; 2017 Jun; 19(6):862-870. PubMed ID: 28339588
[TBL] [Abstract][Full Text] [Related]
7. The impact of adjuvant therapy for patients with high-risk diffuse WHO grade II glioma.
Youland RS; Kreofsky CR; Schomas DA; Brown PD; Buckner JC; Laack NN
J Neurooncol; 2017 Dec; 135(3):535-543. PubMed ID: 28836106
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of the isocitrate dehydrogenase 1 single-nucleotide polymorphism rs11554137 in malignant gliomas.
Wang XW; Boisselier B; Rossetto M; Marie Y; Idbaih A; Mokhtari K; Gousias K; Hoang-Xuan K; Delattre JY; Simon M; Labussière M; Sanson M
Cancer; 2013 Feb; 119(4):806-13. PubMed ID: 23184331
[TBL] [Abstract][Full Text] [Related]
9. Gliomatosis cerebri: clinical characteristics, management, and outcomes.
Chen S; Tanaka S; Giannini C; Morris J; Yan ES; Buckner J; Lachance DH; Parney IF
J Neurooncol; 2013 Apr; 112(2):267-75. PubMed ID: 23341100
[TBL] [Abstract][Full Text] [Related]
10. Wide Range of Clinical Outcomes in Patients with Gliomatosis Cerebri Growth Pattern: A Clinical, Radiographic, and Histopathologic Study.
Ly KI; Oakley DH; Pine AB; Frosch MP; Chiou SH; Betensky RA; Pomerantz SR; Hochberg FH; Batchelor TT; Cahill DP; Dietrich J
Oncologist; 2019 Mar; 24(3):402-413. PubMed ID: 30097523
[TBL] [Abstract][Full Text] [Related]
11. IDH1 status is significantly different between high-grade thalamic and superficial gliomas.
Zuo M; Li M; Chen N; Yu T; Kong B; Liang R; Wang X; Mao Q; Liu Y
Cancer Biomark; 2017 Aug; 20(2):183-189. PubMed ID: 28869450
[TBL] [Abstract][Full Text] [Related]
12. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
Hartmann C; Hentschel B; Wick W; Capper D; Felsberg J; Simon M; Westphal M; Schackert G; Meyermann R; Pietsch T; Reifenberger G; Weller M; Loeffler M; von Deimling A
Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844
[TBL] [Abstract][Full Text] [Related]
13. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
Wick W; Hartmann C; Engel C; Stoffels M; Felsberg J; Stockhammer F; Sabel MC; Koeppen S; Ketter R; Meyermann R; Rapp M; Meisner C; Kortmann RD; Pietsch T; Wiestler OD; Ernemann U; Bamberg M; Reifenberger G; von Deimling A; Weller M
J Clin Oncol; 2009 Dec; 27(35):5874-80. PubMed ID: 19901110
[TBL] [Abstract][Full Text] [Related]
14. Gliomatosis cerebri: 20 years of experience at the Children's Hospital of Philadelphia.
Armstrong GT; Phillips PC; Rorke-Adams LB; Judkins AR; Localio AR; Fisher MJ
Cancer; 2006 Oct; 107(7):1597-606. PubMed ID: 16955507
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Radiation Therapy Alone and Chemotherapy Alone for Low-Grade Gliomas without Surgical Resection.
Wu J; Kim C; Bai HX; Tang L; Wang Y; Li X; Zhang Z; Karakousis G; Huang R; Zhang PJ; Xiao B; Yang L
World Neurosurg; 2019 Feb; 122():e108-e120. PubMed ID: 30261385
[TBL] [Abstract][Full Text] [Related]
16. Subgroup characteristics of insular low-grade glioma based on clinical and molecular analysis of 42 cases.
Tang C; Zhang ZY; Chen LC; Sun Z; Zhang Y; Qin Z; Yao Y; Zhou LF
J Neurooncol; 2016 Feb; 126(3):499-507. PubMed ID: 26586262
[TBL] [Abstract][Full Text] [Related]
17. Patterns of Tumor Contrast Enhancement Predict the Prognosis of Anaplastic Gliomas with IDH1 Mutation.
Wang YY; Wang K; Li SW; Wang JF; Ma J; Jiang T; Dai JP
AJNR Am J Neuroradiol; 2015 Nov; 36(11):2023-9. PubMed ID: 26316565
[TBL] [Abstract][Full Text] [Related]
18. IDH1 mutation, a genetic alteration associated with adult gliomatosis cerebri.
Narasimhaiah D; Miquel C; Verhamme E; Desclée P; Cosnard G; Godfraind C
Neuropathology; 2012 Feb; 32(1):30-7. PubMed ID: 21481010
[TBL] [Abstract][Full Text] [Related]
19. Combined IDH1 mutation and MGMT methylation status on long-term survival of patients with cerebral low-grade glioma.
Tanaka K; Sasayama T; Mizukawa K; Takata K; Sulaiman NS; Nishihara M; Kohta M; Sasaki R; Hirose T; Itoh T; Kohmura E
Clin Neurol Neurosurg; 2015 Nov; 138():37-44. PubMed ID: 26276726
[TBL] [Abstract][Full Text] [Related]
20. Mutated IDH1 is a favorable prognostic factor for type 2 gliomatosis cerebri.
Kwon MJ; Kim ST; Kwon MJ; Kong DS; Lee D; Park S; Kang SY; Song JY; Nam DH; Kato Y; Choi YL; Suh YL
Brain Pathol; 2012 May; 22(3):307-17. PubMed ID: 21929658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]